Contineum Therapeutics Sees Unusually Large Options Volume (NASDAQ:CTNM)

Posted by Francis Steltz on Sep 17th, 2026

Contineum Therapeutics, Inc. (NASDAQ:CTNM – Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors purchased 10,034 call options on the company. This is an increase of approximately 4,420% compared to the average volume of 222 call options.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on CTNM shares. Robert W. Baird lowered their target price on shares of Contineum Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Friday, July 17th. JonesTrading reduced their price objective on shares of Contineum Therapeutics from $26.00 to $24.00 and set a “buy” rating on the stock in a report on Tuesday. Royal Bank Of Canada boosted their target price on Contineum Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Finally, Wall Street Zen raised shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.

View Our Latest Analysis on Contineum Therapeutics

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CTNM. Royal Bank of Canada grew its holdings in shares of Contineum Therapeutics by 73.5% during the first quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock worth $76,000 after purchasing an additional 2,454 shares during the last quarter. Cannon Global Investment Management LLC acquired a new stake in Contineum Therapeutics during the 1st quarter worth $170,000. Independent Financial Group LLC acquired a new position in shares of Contineum Therapeutics in the 1st quarter valued at approximately $353,000. Seven Fleet Capital Management LP acquired a new position in Contineum Therapeutics in the 1st quarter worth $353,000. Finally, Bank of America Corp DE grew its stake in shares of Contineum Therapeutics by 411.9% during the 1st quarter. Bank of America Corp DE now owns 47,449 shares of the company’s stock worth $620,000 after acquiring an additional 38,180 shares in the last quarter.

Contineum Therapeutics Stock Down 2.9%

NASDAQ CTNM traded down $0.40 during trading hours on Thursday, hitting $13.36. The company had a trading volume of 157,762 shares, compared to its average volume of 328,664. The business has a fifty day simple moving average of $15.31 and a 200-day simple moving average of $14.02. The firm has a market cap of $502.60 million, a P/E ratio of -7.72 and a beta of 0.75. Contineum Therapeutics has a fifty-two week low of $8.60 and a fifty-two week high of $17.78.

Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05. Equities analysts forecast that Contineum Therapeutics will post -1.68 EPS for the current fiscal year.

Contineum Therapeutics Company Profile

(Get Free Report)

Contineum Therapeutics, formerly known as Pipeline Therapeutics, is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for diseases of the central nervous system. The company’s research is aimed at promoting remyelination and neurorepair, processes that may restore damaged nerve function rather than solely managing disease symptoms.

Contineum’s lead programs include PIPE-307, an oral, brain-penetrant therapy designed to promote remyelination through selective inhibition of the M1 muscarinic receptor, and PIPE-791, an oral antagonist of the lysophosphatidic acid receptor 1.